Peter Bernhardt

List of Publications by Year
in descending order

60 papers	1,726 citations	279798 23 h-index	289244 40 g-index
62 all docs	62 docs citations	62 times ranked	1554 citing authors

#	Article	IF	Citations
1	EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1778-1809.	6.4	70
2	Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3830-3840.	6.4	30
3	Preclinical investigations using [177Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3639-3650.	6.4	9
4	Pituitary Function after High-Dose ^{177}Lu-DOTATATE Therapy and Long-Term Follow-Up. Neuroendocrinology, 2021, 111, 344-353.	2.5	12
5	Promising potential of [177Lu]Lu-DOTA-folate to enhance tumor response to immunotherapy—a preclinical study using a syngeneic breast cancer model. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 984-994.	6.4	16
6	Deep-Learning Generation of Synthetic Intermediate Projections Improves ^{177}Lu SPECT Images Reconstructed with Sparsely Acquired Projections. Journal of Nuclear Medicine, 2021, 62, 528-535.	5.0	25
7	OPTIMISATION IN X-RAY AND MOLECULAR IMAGING 2020. Radiation Protection Dosimetry, 2021, 195, 133-133.	0.8	0
8	First-in-Humans Application of ^{161}Tb: A Feasibility Study Using ^{161}Tb-DOTATOC. Journal of Nuclear Medicine, 2021, 62, 1391-1397.	5.0	42
9	Evaluation of SSTR2 Expression in SI-NETs and Relation to Overall Survival after PRRT. Cancers, 2021, 13, 2035.	3.7	7
10	Dosimetric Analysis of the Short-Ranged Particle Emitter 161Tb for Radionuclide Therapy of Metastatic Prostate Cancer. Cancers, 2021, 13, 2011.	3.7	19
11	Evaluation of the Spatial Resolution In monte Carlo-Based Spect/Ct Reconstruction Of 111In-Octreotide Images. Radiation Protection Dosimetry, 2021, 195, 319-326.	0.8	3
12	Activity Concentration Estimation in Automated Kidney Segmentation Based on Convolution Neural Network Method for 177LU–SPECT/CT Kidney Dosimetry. Radiation Protection Dosimetry, 2021, 195, 164-171.	0.8	3
13	Artificial intelligence and the medical physics profession - A Swedish perspective. Physica Medica, 2021, 88, 218-225.	0.7	6
14	Optimizing the Schedule of PARP Inhibitors in Combination with 177Lu-DOTATATE: A Dosimetry Rationale. Biomedicines, 2021, 9, 1570.	3.2	4
15	EANM dosimetry committee series on standard operational procedures: a unified methodology for 99mTc-MAA pre- and 90Y peri-therapy dosimetry in liver radioembolization with 90Y microspheres. EJNMMI Physics, 2021, 8, 77.	2.7	61
16	Terbium radionuclides for theranostics. , 2021, , .		0
17	Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile. Molecules, 2020, 25, 2542.	3.8	12
18	Establishment of a clinical SPECT/CT protocol for imaging of 161Tb. EJNMMI Physics, 2020, 7, 45.	2.7	20

#	Article	IF	Citations
19	Combination of Proton Therapy and Radionuclide Therapy in Mice: Preclinical Pilot Study at the Paul Scherrer Institute. Pharmaceutics, 2019, 11, 450.	4.5	4
20	Therapeutic Potential of 47Sc in Comparison to 177Lu and 90Y: Preclinical Investigations. Pharmaceutics, 2019, 11, 424.	4.5	24
21	Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1919-1930.	6.4	109
22	Bone Marrow Absorbed Doses and Correlations with Hematologic Response During ^{177}Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases. Journal of Nuclear Medicine, 2019, 60, 1406-1413.	5.0	41
23	Re: Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2019, 30, 2047-2048.	0.5	3
24	Alpha-PET for Prostate Cancer: Preclinical investigation using 149Tb-PSMA-617. Scientific Reports, 2019, 9, 17800.	3.3	49
25	Mars â€" a target for teachers and science students. Proceedings of the International Astronomical Union, 2019, 15, 449-450.	0.0	0
26	Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy. EJNMMI Physics, 2018, 5, 12.	2.7	60
27	Fast GPU-based Monte Carlo code for SPECT/CT reconstructions generates improved 177Lu images. EJNMMI Physics, 2018, 5, 1.	2.7	41
28	Autoradiography and biopsy measurements of a resected hepatocellular carcinoma treated with 90 yttrium radioembolization demonstrate large absorbed dose heterogeneities. Advances in Radiation Oncology, 2018, 3, 439-446.	1.2	3
29	Preclinical Comparison of Albumin-Binding Radiofolates: Impact of Linker Entities on the in Vitro and in Vivo Properties. Molecular Pharmaceutics, 2017, 14, 523-532.	4.6	44
30	Segmentation of Whole-Body Images into Two Compartments in Model for Bone Marrow Dosimetry Increases the Correlation with Hematological Response in 177Lu-DOTATATE Treatments. Cancer Biotherapy and Radiopharmaceuticals, 2017, 32, 335-343.	1.0	6
31	Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1480-1489.	6.4	144
32	NAMPT Inhibitor GMX1778 Enhances the Efficacy of ^{177}Lu-DOTATATE Treatment of Neuroendocrine Tumors. Journal of Nuclear Medicine, 2017, 58, 288-292.	5.0	33
33	IMPROVED PLANAR KIDNEY ACTIVITY CONCENTRATION ESTIMATE BY THE POSTERIOR VIEW METHOD IN177LU-DOTATATE TREATMENTS. Radiation Protection Dosimetry, 2016, 169, 259-266.	0.8	2
34	Radiation exposure of the spleen during 177Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volume. EJNMMI Physics, 2016, 3, 15.	2.7	28
35	A novel planar image-based method for bone marrow dosimetry in 177Lu-DOTATATE treatment correlates with haematological toxicity. EJNMMI Physics, 2016, 3, 21.	2.7	36
36	Simulation Model of Microsphere Distribution for Selective Internal Radiation Therapy Agrees With Observations. International Journal of Radiation Oncology Biology Physics, 2016, 96, 414-421.	0.8	5

#	Article	IF	Citations
37	Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of 161Tb-folate and 177Lu-folate. EJNMMI Research, 2016, 6, 13.	2.5	43
38	A new quantitative image-based method for evaluation of bony temporal hollowing in metopic synostosis. Journal of Plastic Surgery and Hand Surgery, 2016, 50, 343-348.	0.8	7
39	IMAGE FUSION OF RECONSTRUCTED DIGITAL TOMOSYNTHESIS VOLUMES FROM A FRONTAL AND A LATERAL ACQUISITION. Radiation Protection Dosimetry, 2016, 169, 410-415.	0.8	1
40	A novel statistical analysis method to improve the detection of hepatic foci of 111In-octreotide in SPECT/CT imaging. EJNMMI Physics, 2016, 3, 1.	2.7	21
41	Oxygen Distributions—Evaluation of Computational Methods, Using a Stochastic Model for Large Tumour Vasculature, to Elucidate the Importance of Considering a Complete Vascular Network. PLoS ONE, 2016, 11, e0166251.	2.5	0
42	Increased absorbed liver dose in Selective Internal Radiation Therapy (SIRT) correlates with increased sphere-cluster frequency and absorbed dose inhomogeneity. EJNMMI Physics, 2015, 2, 10.	2.7	20
43	Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy. Nuclear Medicine and Biology, 2015, 42, 770-779.	0.6	38
44	Absorbed Doses and Risk Estimates of 211At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2015, 93, 569-576.	0.8	45
45	Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 947-955.	6.4	79
46	The impact of including spatially longitudinal heterogeneities of vessel oxygen content and vascular fraction in 3D tumor oxygenation models on predicted radiation sensitivity. Medical Physics, 2014, 41, 044101.	3.0	6
47	Heterogeneity of microsphere distribution in resected liver and tumour tissue following selective intrahepatic radiotherapy. EJNMMI Research, 2014, 4, 48.	2.5	23
48	Intracranial Volume in 15 Children with Bilateral Coronal Craniosynostosis. Plastic and Reconstructive Surgery - Global Open, 2014, 2, e243.	0.6	12
49	Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 476-485.	6.4	86
50	Promising Prospects for [44]Sc-/[47]Sc-Based Theragnostics: Application of [47]Sc for Radionuclide Tumor Therapy in Mice. Journal of Nuclear Medicine, 2014, 55, 1658-1664.	5.0	163
51	Oxygen distribution in tumors: A qualitative analysis and modeling study providing a novel Monte Carlo approach. Medical Physics, 2014, 41, 094101.	3.0	3
52	A Novel Quantitative Image-Based Method for Evaluating Cranial Symmetry and Its Usefulness in Patients Undergoing Surgery for Unicoronal Synostosis. Journal of Craniofacial Surgery, 2013, 24, 166-169.	0.7	6
53	Radiation exposure during liver surgery after treatment with ^{90}Y microspheres, evaluated with computer simulations and dosimeter measurements. Journal of Radiological Protection, 2012, 32, 439-446.	1.1	6
54	Effects of Treatment with 177Lu-DOTA-Tyr3-Octreotate on Uptake of Subsequent Injection in Carcinoid-Bearing Nude Mice. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 644-653.	1.0	22

#	Article	IF	Citations
55	Dosimetric characterization of radionuclides for systemic tumor therapy: Influence of particle range, photon emission, and subcellular distribution. Medical Physics, 2006, 33, 3260-3269.	3.0	40
56	Biodistribution data from 100 patients i.v. injected with111in-DTPA-D-Phe1-Octreotide. Acta Oncológica, 2004, 43, 436-442.	1.8	30
57	Modelling of metastatic cure after radionuclide therapy: Influence of tumor distribution, cross-irradiation, and variable activity concentration. Medical Physics, 2004, 31, 2628-2635.	3.0	13
58	Biodistribution of 111in-DTPA-D-Phe1-octreotide in tumor-bearing nude mice: influence of amount injected and route of administration. Nuclear Medicine and Biology, 2003, 30, 253-260.	0.6	23
59	Model of metastatic growth valuable for radionuclide therapy. Medical Physics, 2003, 30, 3227-3232.	3.0	22
60	Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors. International Journal of Radiation Oncology Biology Physics, 2001, 51, 514-524.	0.8	46